Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines

Nachi Namatame, Naomi Tamaki, Yuya Yoshizawa, Mutsumi Okamura, Yumiko Nishimura, Kanami Yamazaki, Miwa Tanaka, Takuro Nakamura, Kentaro Semba, Takao Yamori, Shin Ichi Yaguchi, Shingo Dan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Treatment of patients with advanced sarcoma remains challenging due to lack of effective medicine, with the development of novel drugs being of keen interest. A pan-PI3K inhibitor, ZSTK474, has been evaluated in clinical trials against a range of advanced solid tumors, with clinical benefit shown in sarcoma patients. In the present study, we developed a panel of 14 human sarcoma cell lines and investigated the antitumor effect of 24 anticancer agents including ZSTK474, other PI3K inhibitors, and those clinically used for sarcoma treatment. ZSTK474 exhibited a similar antiproliferative profile to other PI3K inhibitors but was clearly different from the other drugs examined. Indeed, ZSTK474 inhibited PI3K-downstream pathways, in parallel to growth inhibition, in all cell lines examined, showing proof-of-concept of PI3K inhibition. In addition, ZSTK474 induced apoptosis selectively in Ewing's sarcoma (RD-ES and A673), alveolar rhabdomyosarcoma (SJCRH30) and synovial sarcoma (SYO-1, Aska-SS and Yamato-SS) cell lines, all of which harbor chromosomal translocation and resulting oncogenic fusion genes, EWSR1-FLI1, PAX3-FOXO1 and SS18-SSX, respectively. Finally, animal experiments confirmed the antitumor activity of ZSTK474 in vivo, with superior efficacy observed in translocation-positive cells. These results suggest that ZSTK474 could be a promising drug candidate for treating sarcomas, especially those harboring chromosomal translocation.

Original languageEnglish
Pages (from-to)35141-35161
Number of pages21
JournalOncotarget
Volume9
Issue number80
DOIs
Publication statusPublished - 2018 Oct 1

Keywords

  • Anticancer agent
  • Cell line panel
  • Oncogenic chromosomal translocation
  • PI3K
  • Sarcoma

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines'. Together they form a unique fingerprint.

  • Cite this

    Namatame, N., Tamaki, N., Yoshizawa, Y., Okamura, M., Nishimura, Y., Yamazaki, K., Tanaka, M., Nakamura, T., Semba, K., Yamori, T., Yaguchi, S. I., & Dan, S. (2018). Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines. Oncotarget, 9(80), 35141-35161. https://doi.org/10.18632/oncotarget.26216